Human papillomavirus L1-specific CD4+ T-cell receptor (HPV L1 TCR)

The Human Papillomavirus (HPV) L1-specific CD4+ T-cell receptor is a specialized immune receptor found on the surface of helper T-cells that specifically recognizes the major capsid protein L1 of HPV (Source: PubMed). This recognition is mediated by the presentation of L1-derived peptides on HLA class II molecules, such as HLA-DR, which are typically expressed on professional antigen-presenting cells (Source: NIH). Upon binding to the peptide-MHC complex, the TCR triggers a signaling cascade through the CD3 complex, leading to the activation and proliferation of CD4+ T-cells (Source: Nature). These activated cells play a pivotal role in the immune system by secreting cytokines like interferon-gamma and providing essential help to B-cells for the production of neutralizing antibodies against the virus (Source: Journal of Virology). In clinical applications, this TCR is the primary mediator of the protective immunity elicited by prophylactic HPV vaccines, including Gardasil 9 and Cervarix (Source: FDA). Beyond prevention, researchers are exploring the use of these TCRs in adoptive cell therapies, where T-cells are engineered to express high-affinity HPV L1-specific receptors to treat persistent infections or early-stage malignancies (Source: Frontiers in Immunology). While most therapeutic focus in HPV-related cancers is on E6 and E7 oncoproteins, L1-specific TCRs remain critical for understanding vaccine efficacy and developing broad-spectrum immunotherapies (Source: Clinical Cancer Research). Safety considerations for targeting or utilizing these receptors include the risk of off-target cross-reactivity with human self-peptides and the potential for systemic inflammatory responses like cytokine release syndrome (Source: Molecular Therapy).

Other names

CD4+ T-cell receptor recognizing HPV L1-derived peptides presented on HLA class IIHPV L1-specific TCRMHC class II-restricted HPV L1 TCRHPV L1-specific CD4+ TCR

The TCR complex recognizes HPV L1-derived peptides presented on HLA class II molecules, initiating intracellular signaling via the CD3 complex that leads to CD4+ T-cell activation, proliferation, and the coordination of the adaptive immune response against HPV.